SPEECH-PROCESSING
Speech Processing Solutions , the market leader in professional dictation, has announced that its portfolio of speech-to-text software is now available on a subscription basis. Flexible low monthly subscription costs make it easier for organizations to take advantage of the full range of available speech-to-text services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005443/en/
Philips dictation and transcription software streamlines the document creation process and facilitates communication between authors and transcriptionists. It enables everything from automated file routing to an on-demand “pay as you go” transcription service or automatic speech recognition to help business of all sizes fulfill their unique needs.
“Philips speech-to-text software helps businesses reach their goals by helping them become even more efficient, profitable and successful, whether this means scoring new top clients or simply having more time for their current customers,” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions.
High-tech innovation to boost voice-based productivity
Philips software is designed around the customers’ needs and has been developed in close collaboration with end-users. Philips understands that different businesses have personalized needs and preferences. Regardless of whether they are small, mid-sized or large, prefer an on-premise or cloud solution, or run an environment with a few laptops or a complex multi-branch setup across several countries, various voice-to-text options are available to help organizations address every business requirement.
The subscription-based speech-to-text portfolio includes Philips SpeechExec Pro, Philips SpeechExec Enterprise and SpeechLive. The new Philips SpeechExec Pro version 11.5 features a refreshed, more user-friendly interface and supports the latest operating systems available in the market. SpeechLive, Philips’s web dictation and transcription solution, now boasts a brand-new speech-to-text service that offers users speech recognition in real-time. This not only saves users time while working on documents, but also money and hassle as no additional speech recognition software needs to be purchased and installed. SpeechLive offers constant file access to increase mobility, helping professionals to work from anywhere and at any time. Now available as a one- or two-year subscription package, Philips SpeechExec Enterprise, which is ideal for large, multi-branch businesses, supports workflow processes that require central administration and virtual environments.
“Quick and effective communication is key in today’s complex business world. Working in a fast-paced environment requires effortless collaboration and efficient processes no matter what the size of your organization. Our Philips workflow software solutions allow you to do just that, while new subscription models enable businesses to be more agile and cost-efficient than ever before,” explains Dr. Brauner.
All Philips software is optimized to support the industry-leading range of Philips dictation devices including the SpeechMike series, the hands-free dictation headset SpeechOne and the Android-based SpeechAir.
For a free trial of Philips workflow solutions, go to: www.philips.com/speech
About Speech Processing Solutions
Speech Processing Solutions (SPS) is an international technology company and a global leader in dictation solutions. More than four million users worldwide work with speech-to-text solutions developed by SPS and sold under the Philips brand. These solutions include web-based and desktop workflow software as well as dictation devices. These smart solutions save users’ time and allow them to focus on their core tasks, making their business more efficient, customer-centric and profitable.
Headquartered in Vienna, Austria, SPS has regional offices in the United States, Canada, Australia, the United Kingdom, Germany, France, Belgium and Austria, as well as a network of more than 1000 distribution and implementation partners worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005443/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
2026 Mitsui Chemicals Catalysis Science Awards18.11.2025 03:00:00 CET | Press release
Online applications are open until December 25, 2025 Mitsui Chemicals, Inc. has announced that online applications for the 2026 Mitsui Chemicals Catalysis Science Award have been open since September 1, 2025. The application period will run from September 1 to December 25, 2025. Aiming to contribute to the sustainable development of chemistry and the chemical industry, Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Awards in 2004. The awards consist of the Catalysis Science Award and the Catalysis Science Award for Creative Work, which recognize outstanding achievements in the field of catalysis science. To date, the awards have been conferred on 33 researchers within Japan and overseas. Past recipients include individuals who have gone on to be highly acclaimed worldwide, receiving honors such as the Nobel Prize in Chemistry and other prestigious Japanese and international awards. We welcome applications from a wide range of R&D fields, including solid catalysts,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
